Neuroprotection in Parkinson's Disease; a Commentary

Author： Gatto Emilia Mabel   Riobó Natalia   Carreras MarÍa Cecilia   Poderoso Juan José   Micheli Federico E.  

Publisher： Springer Publishing Company

ISSN： 1029-8428

Source： Neurotoxicity Research, Vol.4, Iss.2, 2002-01, pp. : 141-145

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Parkinson's disease, insulin resistance and novel agents of neuroprotection

By Aviles-Olmos Iciar  

Brain, Vol. 136, Iss. 2, 2013-02 ,pp. : 374-384

Oxford University Press

Access to resources Recommend Favorite

Gene Therapeutic Strategies for Neuroprotection: Implications for Parkinson's Disease

By Bowers W.J.   Howard D.F.   Federoff H.J.  

Experimental Neurology, Vol. 144, Iss. 1, 1997-03 ,pp. : 58-68

Elsevier

Access to resources Recommend Favorite

Neuroprotection of Pramipexole in UPS Impairment Induced Animal Model of Parkinson’s Disease

By Li Chao   Guo Yuan   Xie Wenjie   Li Xingang   Janokovic Joseph   Le Weidong  

Neurochemical Research, Vol. 35, Iss. 10, 2010-10 ,pp. : 1546-1556

Springer Publishing Company

Access to resources Recommend Favorite

Neuroprotection for Parkinson's disease: a call for clinically driven experimental design

By Bezard E.  

Lancet Neurology, Vol. 2, Iss. 7, 2003-07 ,pp. : 393-393

Elsevier

Access to resources Recommend Favorite

Defining premotor Parkinson's disease: a window of opportunity for neuroprotection?

By Mahlknecht Philipp   Poewe Werner  

Neurodegenerative Disease Management, Vol. 3, Iss. 1, 2013-02 ,pp. : 61-70

Future Medicine

Access to resources Recommend Favorite